文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

高负担国家结核治疗中药敏试验与死亡率:多中心队列研究

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.
PubMed 文献 · Lancet Infect Dis · 2019-02-08

该多中心队列研究纳入科特迪瓦、刚果民主共和国、肯尼亚、尼日利亚、南非、秘鲁和泰国2013至2016年诊断的634例成人结核患者,比较本地与参考实验室药敏试验结果一致性及治疗 adequacy 与死亡的关系。

要点

  • 耐药株治疗不足患者死亡率达57%(8/14),而敏感株按WHO指南治疗者为6%(20/336)。
  • 建议诊断时对一线和二线药物进行快速分子药敏试验以改善MDR及pre-XDR/XDR结核结局。

核心结论

  • 与参考标准相比不准确的药敏试验导致耐药结核治疗不足并增加死亡率。
  • 诊断时需对一线和二线药物进行快速分子药敏试验以改善MDR及pre-XDR/XDR结核患者结局。

研究设计与样本

  • 多中心队列研究,在科特迪瓦、刚果民主共和国、肯尼亚、尼日利亚、南非、秘鲁和泰国开展。
  • 收集2013至2016年诊断的16岁及以上成人结核患者分离株和临床数据,最终纳入634例分析。
  • 本地及瑞士国家分枝杆菌中心进行分子或表型药敏试验,采用多因素logistic回归调整性别、年龄、痰涂片和HIV状态。

主要发现

  • 参考实验室药敏显示全敏感394株(62%)、单耐药45株(7%)、MDR 163株(26%)、pre-XDR或XDR 30株(5%)。
  • 本地与参考实验室结果一致513例(81%),不一致121例(19%)。

临床怎么用

  • 对MDR及pre-XDR/XDR结核患者,诊断时应采用快速分子药敏试验检测一线和二线药物。
  • 应重视本地药敏结果与参考实验室的一致性,避免因结果不一致导致治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug resistance is a challenge for the global control of tuberculosis. We examined mortality in patients with tuberculosis from high-burden countries, according to concordance or discordance of results from drug susceptibility testing done locally and in a reference laboratory. METHODS: This multicentre cohort study was done in Côte d'Ivoire, Democratic Republic of the Congo, Kenya, Nigeria, South Africa, Peru, and Thailand. We collected Mycobacterium tuberculosis isolates and clinical data from adult patients aged 16 years or older. Patients were stratified by HIV status and tuberculosis drug resistance. Molecular or phenotypic drug susceptibility testing was done locally and at the Swiss National Center for Mycobacteria, Zurich, Switzerland. We examined mortality during treatment according to drug susceptibility test results and treatment adequacy in multivariable logistic regression models adjusting for sex, age, sputum microscopy, and HIV status. FINDINGS: We obtained M tuberculosis isolates from 871 patients diagnosed between 2013 and 2016. After exclusion of 237 patients, 634 patients with tuberculosis were included in this analysis; the median age was 33·2 years (IQR 26·9-42·5), 239 (38%) were women, 272 (43%) were HIV-positive, and 69 (11%) patients died. Based on the reference laboratory drug susceptibility test, 394 (62%) strains were pan-susceptible, 45 (7%) monoresistant, 163 (26%) multidrug-resistant (MDR), and 30 (5%) had pre-extensively or extensively drug resistant (pre-XDR or XDR) tuberculosis. Results of reference and local laboratories were concordant for 513 (81%) of 634 patients and discordant for 121 (19%) of 634. Overall, sensitivity to detect any resistance was 90·8% (95% CI 86·5-94·2) and specificity 84·3% (80·3-87·7). Mortality ranged from 6% (20 of 336) in patients with pan-susceptible tuberculosis treated according to WHO guidelines to 57% (eight of 14) in patients with resistant strains who were under-treated. In logistic regression models, compared with concordant drug susceptibility test results, the adjusted odds ratio of death was 7·33 (95% CI 2·70-19·95) for patients with discordant results potentially leading to under-treatment. INTERPRETATION: Inaccurate drug susceptibility testing by comparison with a reference standard leads to under-treatment of drug-resistant tuberculosis and increased mortality. Rapid molecular drug susceptibility test of first-line and second-line drugs at diagnosis is required to improve outcomes in patients with MDR tuberculosis and pre-XDR or XDR tuberculosis. FUNDING: National Institutes of Allergy and Infectious Diseases, Swiss National Science Foundation, Swiss National Center for Mycobacteria.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zürcher K, Ballif M, Fenner L, et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis. 2019. PMID: 30744962. doi:10.1016/S1473-3099(18)30673-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。